CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

CAR T-Cell Therapy Shows Potential in Head and Neck Cancer

April 19th 2017

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

Lead ZUMA-1 Researcher Highlights CAR T Cell Findings in NHL

April 12th 2017

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

April 6th 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Expert Summarizes State of CAR T-Cell Therapy in Hematologic Malignancies

April 6th 2017

Alfred L. Garfall, MD, discusses the latest developments with CAR T-cell therapy in hematologic malignancies

CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response

April 4th 2017

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

CAR T-Cell Response Rate Tops 80% in NHL Trial

April 4th 2017

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Dr. Papa on Challenges of CAR T-Cell Therapy in Head and Neck Cancer

April 1st 2017

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

FDA Grants Priority Review to CTL019 for ALL

March 30th 2017

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

CRISPR Builds More Powerful CAR T Cells

March 24th 2017

Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.

Expert Discusses CAR T-Cell Advances in ALL

March 23rd 2017

Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.

Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies

March 22nd 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

March 6th 2017

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK

March 6th 2017

Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.

Juno Accelerates Development of JCAR017, Halts JCAR015

March 2nd 2017

Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.

Pivotal Year Looms for CAR T-Cell Therapies

March 1st 2017

Chimeric antigen receptor T-cell therapies have already produced clinical trial results that, even by the lofty standards set by emerging immunotherapies, have been stunning.

Axicabtagene Ciloleucel Shows High CR Rates in Primary Analysis of ZUMA-1 Study

February 28th 2017

Treatment with axicabtagene ciloleucel demonstrated an objective response rate of 82% and a complete response rate of 54% for patients with aggressive non-Hodgkin lymphoma.

Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy

February 26th 2017

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19

February 17th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.

Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-Cells

February 14th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.